Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Good posting Krone. A point of interest here:-
The exact impact of JAK inhibitors on a wider spectrum of activation states of macrophages is however still to be determined, especially in the context of disorders involving concomitant activation of pro-inflammatory M1 macrophages and profibrotic M2 macrophages.
I do recall Tim in the early stages approx 12 month ago in one of his presentations stating his reasonings as to why a Tyk2 and Jak 1 inhibitor would likely be more effective than than Jak2 and Jak 3 inhibitors. My understanding is:-
Jak 2 and Jak 3 have a much broader spectrum than Tyk 2. Tyk 2 is far more selective. Jak2 and Jak3 combined press all the right buttons and some of the wrong buttons which then prove to be counterproductive. Tyk2 has all the advantages of Jak2 and in addition greater selectivity. Jak3 reacts with too many enzymes.
Deficiency of JAK3 blocks signaling of the following cytokines and their effects:[9]
IL-2 - T cell proliferation and maintenance of peripheral tolerance
IL-4 - differentiation of Th2 cells
IL-7 - thymocyte development in the thymus
IL-9 - survival signal for various hematopoietic cells
IL-15 - NK cell development
IL-21 - regulation of immunoglobulin class switching in B cells
Since JAK3 is required for immune cell development, targeting JAK3 could be a useful strategy to generate a novel class of immunosuppressant drugs. Moreover, unlike other JAKs, JAK3 is primarily expressed in hematopoietic cells, so a highly specific JAK3 inhibitor should have precise effects on immune cells and minimal pleiotropic defects.[9] The selectivity of a JAK3 inhibitor would also have advantages over the current widely used immunosuppressant drugs, which have abundant targets and diverse side effects. A JAK3 inhibitor could be useful for treating autoimmune diseases, especially those in which a particular cytokine receptor has a direct role on disease pathogenesis. For example, signaling through the IL-15 receptor is known to be important in the development rheumatoid arthritis,[27] and the receptors for IL-4 and IL-9 play roles in the development of allergic responses.
JAK3 is activated only by cytokines whose receptors contain the common gamma chain (?c) subunit: IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21.
No mention in the report of Jak1 or Tyk2 ( wonders why)
With regards to Jak1 and I believe this to be advantageous in SDC1801
Also, one study indicates that JAK1 is needed to carry out signalling for receptors of the cytokines IFN?, IL-2, IL-4 and IL-10.['
in addition
Selective inhibition of JAK3, JAK1 or Tyk2 provides the opportunity to achieve clinical efficacy in the treatment of inflammatory diseases while reducing the risk of dose-limiting effects attributable to JAK2 inhibition.'
Apologies if appears a little disorganised, called into work early
Regards
Hope the likes of GSK takes a swipe at Sareum and we all benefit ...hold and add..this will reward us for our retirement.
We certainly fit the strategy, "She added that GSK's strategy 'continues to be to focus on the science of the immune system, human genetics and advanced technologies to get ahead of infectious diseases, HIV, cancer and immune-mediated and respiratory diseases'."
https://www.thisismoney.co.uk/money/markets/article-9703741/Emma-Walmsley-takes-huge-axe-GlaxoSmithKline-dividend.html
Given both Tim’s and Michael Owen’s long standing association with GSK it will be interesting to see if GSK is indeed a suitor for Sareum.
Coincidentally whilst researching Hal Barron’s TYK2 interests came across the following https://hal.archives-ouvertes.fr/hal-02888737/document which concludes:
Overall, our results suggest that the combined anti-inflammatory and anti-fibrotic properties of JAK2 inhibitors could be relevant to target lung macrophages in autoimmune and inflammatory pulmonary disorders that have no efficient disease modifying drugs to date. Our results emphasizes the impact of JAK inhibitors on the polarization states of skin and lung macrophages. Beyond the issue of polarization profile, the impact of JAK inhibitors on the functional resolving properties of macrophages may also represent a relevant issue for the treatment of pulmonary and systemic disorders and this question may deserves dedicated studies in the future (1,2,28, 68).
CRediT authorship contribution state